MedPath

BAUSCH HEALTH AMERICAS, INC.

🇺🇸United States
Ownership
Subsidiary
Employees
3.1K
Market Cap
-
Website
http://www.bauschhealth.com

Dose Ranging Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Budesonide Rectal Foam in Pediatric Patients Aged 5 to 17 Years With Active, Mild to Moderate Distal Ulcerative Colitis

Phase 4
Not yet recruiting
Conditions
Ulcerative Colitis
Interventions
First Posted Date
2023-08-04
Last Posted Date
2023-08-04
Lead Sponsor
Bausch Health Americas, Inc.
Target Recruit Count
100
Registration Number
NCT05976802

Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis

Phase 3
Active, not recruiting
Conditions
Hepatic Encephalopathy
Interventions
Drug: Placebo
Drug: Rifaximin SSD
First Posted Date
2022-03-28
Last Posted Date
2024-05-09
Lead Sponsor
Bausch Health Americas, Inc.
Target Recruit Count
466
Registration Number
NCT05297448
Locations
🇺🇸

Bausch Site 482, Valencia, California, United States

🇺🇸

Bausch Site 452, Miami Lakes, Florida, United States

🇺🇸

Bausch Site 577, Macon, Georgia, United States

and more 184 locations

Safety, Tolerability, and Pharmacokinetics of Inhaled Virazole Administered Via Air-Jet Nebulizer in Healthy Volunteers

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: 50 mg/mL Virazole Inhalant Product
Drug: 100 mg/mL Virazole Inhalant Product
Drug: Placebo
First Posted Date
2022-02-08
Last Posted Date
2022-02-08
Lead Sponsor
Bausch Health Americas, Inc.
Target Recruit Count
32
Registration Number
NCT05229510
Locations
🇨🇦

Bausch Site 1, Mississauga, Ontario, Canada

Canadian Real World Evidence Study of Brodalumab in Plaque Psoriasis to Understand the Impact on Quality of Life and Work Productivity

Active, not recruiting
Conditions
Psoriasis
Interventions
Biological: Brodalumab
Biological: Matched cohort
First Posted Date
2021-11-24
Last Posted Date
2024-10-29
Lead Sponsor
Bausch Health Americas, Inc.
Target Recruit Count
394
Registration Number
NCT05132231
Locations
🇨🇦

CARE Site 52, Saint-Charles-Borromée, Quebec, Canada

🇨🇦

CARE Site 42, Calgary, Alberta, Canada

🇨🇦

CARE Site 26, Calgary, Alberta, Canada

and more 39 locations

Pharmacokinetics and Pharmacodynamics of Rifaximin Novel Formulations in Patients With Sickle Cell Disease

Phase 2
Completed
Conditions
Sickle Cell Disease
Interventions
Drug: High Dose Rifaximin ER
Drug: Low Dose Rifaximin ER
Drug: Low Dose Rifaximin DER
Drug: Placebo
Drug: High Dose Rifaximin DER
First Posted Date
2021-10-28
Last Posted Date
2023-09-07
Lead Sponsor
Bausch Health Americas, Inc.
Target Recruit Count
44
Registration Number
NCT05098028
Locations
🇺🇸

Bausch Site 105, Orange, California, United States

🇰🇪

Bausch Site 502, Kisumu, Kenya

🇺🇸

Bausch Site 103, Denver, Colorado, United States

and more 5 locations

Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis

Phase 3
Active, not recruiting
Conditions
Hepatic Encephalopathy
Interventions
Drug: Placebo
Drug: Rifaximin SSD
First Posted Date
2021-10-08
Last Posted Date
2024-03-22
Lead Sponsor
Bausch Health Americas, Inc.
Target Recruit Count
524
Registration Number
NCT05071716
Locations
🇺🇸

Bausch Site 219, Atlanta, Georgia, United States

🇺🇸

Bausch Site 140, Los Angeles, California, United States

🇺🇸

Bausch Site 189, Los Angeles, California, United States

and more 147 locations

Safety and Effectiveness of the CLEAR + BRILLIANT TOUCH(R) Diode Laser 1440-nm and 1927-nm Combination Wavelength Treatment

Not Applicable
Completed
Conditions
Photoaging
Interventions
Device: CLEAR + BRILLIANT TOUCH(R) 1440-nm and 1927-nm handpieces.
First Posted Date
2021-08-30
Last Posted Date
2023-11-22
Lead Sponsor
Bausch Health Americas, Inc.
Target Recruit Count
28
Registration Number
NCT05027282
Locations
🇺🇸

Bausch Site 001, Dallas, Texas, United States

Study to Compare the Safety and Efficacy of IDP-126 Gel to Epiduo® Forte Gel and Vehicle Gel

Phase 2
Completed
Conditions
Acne Vulgaris
Interventions
Drug: IDP-126 Gel
Drug: IDP-126 Vehicle Gel
Drug: Epiduo® Forte Gel
First Posted Date
2021-05-19
Last Posted Date
2023-09-07
Lead Sponsor
Bausch Health Americas, Inc.
Target Recruit Count
686
Registration Number
NCT04892706
Locations
🇺🇸

Bausch Site 142, High Point, North Carolina, United States

🇺🇸

Bausch Site 110, Fremont, California, United States

🇺🇸

Bausch Site 135, North Miami Beach, Florida, United States

and more 39 locations

Study Evaluating Efficacy and Safety of Amiselimod (MT-1303) in Mild to Moderate Ulcerative Colitis

Phase 2
Active, not recruiting
Conditions
Ulcerative Colitis
Interventions
Drug: Placebo
Drug: High Dose MT-1303
Drug: Low Dose MT-1303
First Posted Date
2021-04-23
Last Posted Date
2023-12-15
Lead Sponsor
Bausch Health Americas, Inc.
Target Recruit Count
322
Registration Number
NCT04857112
Locations
🇺🇸

Salix Site 007, Rialto, California, United States

🇺🇸

Bausch Site 008, Lafayette, Louisiana, United States

🇺🇸

Bausch Site 012, Suffolk, Virginia, United States

and more 19 locations

Study to Evaluate the Safety and Efficacy of VIRAZOLE® in Hospitalized Adult Participants With Respiratory Distress Due to COVID-19

Phase 1
Completed
Conditions
COVID19
Interventions
Drug: 50 mg/mL Virazole
Drug: 100 mg/mL Virazole
First Posted Date
2020-09-16
Last Posted Date
2021-08-26
Lead Sponsor
Bausch Health Americas, Inc.
Target Recruit Count
51
Registration Number
NCT04551768
Locations
🇬🇷

Bausch Health Site 201, Athens, Attika, Greece

🇬🇷

Bausch Health Site 204, Alexandroupoli, Evros, Greece

🇲🇽

Bausch Site 304, Tijuana, Zona Rio, Mexico

and more 1 locations
© Copyright 2025. All Rights Reserved by MedPath